Inferra AI / Company / GENB
Generate Biomedicines, Inc.
GENB · Health Care
Last earnings Aug 6, 2026
AI analysis
Q1 2026 · reported May 7, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
stockholders (61,446 ) (41,685 ) Convertible preferred stock accrued dividends (7,749 ) (11,592 ) Net loss attributable to Generate Biomedicines, Inc.
Event summary
Financial Results Cash, cash equivalents, and marketable securities were $516.6 million as of March 31, 2026, compared with
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
stockholders (61,446 ) (41,685 ) Convertible preferred stock accrued dividends (7,749 ) (11,592 ) Net loss attributable to Generate Biomedicines, Inc.
SEC original ↗Generate Biomedicines, Inc. — Earnings release (8-K exhibit)EX-99May 7, 2026
stockholders ( 67,255 ) ( 52,429 ) ( 128,701 ) ( 94,114 ) Convertible preferred stock accrued dividends ( 11,593 ) ( 7,749 ) ( 23,185 ) Net loss attributable to Generate Biomedicines, Inc.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
On an ongoing basis, management evaluates its estimates, which include but are not limited to pre-paid and accrued research and development expenses, liquidity projections, stock-based compensation expense and the incremental borrowing rate for operating and finance lease right-of-use assets, and income taxes.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The assumptions that the Company used to determine the fair value of the Warrant are as follows: March 2, December 31, 2026 2025 Expected term (years) 0.1 0.9 Expected volatility 73.0 % 86.8 % Risk-free interest rate 3.7 % 3.6 % Expected dividend yield 0.0 % 0.0 % Fair value of Series A convertible preferred stock per share $ 11.44 $ 9.29 12 Table of Contents 10.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, preclinical studies and clinical trials, results of preclinical studies and clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Due to the significant resources required for drug development and depending on our ability to access capital, we intend to prioritize the development of GB-0895 for severe asthma.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches.
SEC original ↗Generate Biomedicines, Inc. — Earnings release (8-K exhibit)EX-99May 7, 2026
Additional information on these and other risks and uncertainties that could affect Generate’s business, financial condition, and results of operations is included in Generate’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
SEC original ↗Generate Biomedicines, Inc. — Earnings release (8-K exhibit)EX-99May 7, 2026
Legal Proceedings 33 Item 1A.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements.
SEC original ↗Generate Biomedicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
7 documentsEarnings releases
2 documentsPresentations
0 documentsNo presentations for Generate Biomedicines, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Generate Biomedicines, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.